Ultragenyx Pharmaceutical secured $413 million by selling two FDA priority review vouchers tied to gene-therapy approvals. The company says proceeds will strengthen its financial position for additional deal-making around rare-disease assets. The voucher sales include two separate priorities, both linked to FDA approvals of gene therapies. Ultragenyx framed the transactions as a catalyst for pipeline expansion through further licensing or acquisition activity. For the rare-disease market, the announcement underscores the continued value of FDA’s voucher program as a financing lever for companies with pipeline-building plans.